Advances in drug delivery systems: Work in progress still needed?
Fast dissolving
Nanoparticulate
Osmotic
Selfemulsifying
Vesicular
Journal
International journal of pharmaceutics: X
ISSN: 2590-1567
Titre abrégé: Int J Pharm X
Pays: Netherlands
ID NLM: 101753452
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
04
03
2020
revised:
03
06
2020
accepted:
10
06
2020
entrez:
25
6
2020
pubmed:
25
6
2020
medline:
25
6
2020
Statut:
epublish
Résumé
A new era of science and technology has emerged in pharmaceutical research with focus on developing novel drug delivery systems for oral administration. Conventional dosage forms like tablets and capsules are associated with a low bioavailability, frequent application, side effects and hence patient noncompliance. By developing novel strategies for drug delivery, researchers embraced an alternative to traditional drug delivery systems. Out of those, fast dissolving drug delivery systems are very eminent among pediatrics and geriatrics. Orally disintegrating films are superior over fast dissolving tablets as the latter are assigned with the risk of suffocation. Due to their ability of bypassing the dissolution and the first pass effect after oral administration, self-emulsifying formulations have also become increasingly popular in improving oral bioavailability of hydrophobic drugs. Osmotic devices enable a controlled drug delivery independent upon gastrointestinal conditions using osmosis as driving force. The advances in nanotechnology and the variety of possible materials and formulation factors enable a targeted delivery and triggered release. Vesicular systems can be easily modified as required and provide a controlled and sustained drug delivery to a specific site. This work provides an insight of the novel approaches in drug delivery covering the critical comparison between traditional and novel "advanced-designed" systems.
Identifiants
pubmed: 32577616
doi: 10.1016/j.ijpx.2020.100050
pii: S2590-1567(20)30012-8
pii: 100050
pmc: PMC7305387
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
100050Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2020 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Int J Mol Sci. 2017 Feb 02;18(2):
pubmed: 28157175
Int J Pharm. 2017 Apr 15;521(1-2):73-83
pubmed: 28229944
Int J Pharm. 2016 Jun 15;506(1-2):340-50
pubmed: 27132166
Curr Drug Deliv. 2014;11(1):87-97
pubmed: 24533724
Braz J Med Biol Res. 2013 Jun;46(6):486-501
pubmed: 23802234
AAPS PharmSciTech. 2019 Feb 5;20(3):101
pubmed: 30721444
Carbohydr Polym. 2017 Dec 1;177:194-202
pubmed: 28962758
Int J Pharm. 2013 Aug 30;453(1):215-24
pubmed: 23578826
Pharm Dev Technol. 2016;21(3):328-37
pubmed: 25597782
J Liposome Res. 2016 Sep;26(3):221-32
pubmed: 26621370
Curr Drug Deliv. 2017;14(5):613-633
pubmed: 27199229
Artif Cells Nanomed Biotechnol. 2016;44(1):27-40
pubmed: 24813223
Int J Pharm. 2014 Jan 30;461(1-2):529-39
pubmed: 24374219
J Control Release. 2013 Jul 10;169(1-2):10-6
pubmed: 23591661
Saudi Pharm J. 2018 Jan;26(1):64-70
pubmed: 29379334
Int J Pharm. 2013 Sep 15;454(1):496-511
pubmed: 23415662
J Nanobiotechnology. 2018 Sep 19;16(1):71
pubmed: 30231877
Chem Rev. 2015 Oct 14;115(19):10938-66
pubmed: 26010257
CA Cancer J Clin. 2013 Nov-Dec;63(6):395-418
pubmed: 24114523
Nat Rev Chem. 2017 Aug;1(8):
pubmed: 31286060
Chem Phys Lipids. 2014 Jan;177:8-18
pubmed: 24220497
Drug Deliv. 2016 Nov;23(9):3639-3652
pubmed: 27685505
Pharm Dev Technol. 2015 Jun;20(4):473-89
pubmed: 24490793
Colloids Surf B Biointerfaces. 2013 Dec 1;112:337-43
pubmed: 24012665
Mol Pharm. 2013 Aug 5;10(8):2942-7
pubmed: 23883311
Drug Dev Ind Pharm. 2013 Jan;39(1):1-19
pubmed: 22372916
Int J Pharm. 2014 Nov 20;475(1-2):496-503
pubmed: 25219321
Mater Sci Eng C Mater Biol Appl. 2015 Dec 1;57:414-33
pubmed: 26354282
Eur J Pharm Sci. 2015 Jul 10;74:1-10
pubmed: 25845633
AAPS PharmSciTech. 2014 Feb;15(1):149-60
pubmed: 24222269
Scientifica (Cairo). 2016;2016:6492953
pubmed: 27293976
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015 Sep-Oct;7(5):623-39
pubmed: 25641603
Adv Drug Deliv Rev. 2013 Jan;65(1):17-20
pubmed: 22906864
J Mater Chem B. 2014 Jan 14;2(2):147-166
pubmed: 32261602
Int J Pharm Investig. 2013 Apr;3(2):67-76
pubmed: 24015378
Nanomaterials (Basel). 2019 Apr 19;9(4):
pubmed: 31010180
J Control Release. 2016 May 10;229:10-22
pubmed: 26968799
Drug Deliv. 2017 Nov;24(1):539-557
pubmed: 28181831
Expert Opin Drug Deliv. 2014 Jan;11(1):45-59
pubmed: 24294974
Colloids Surf B Biointerfaces. 2015 Feb 1;126:631-48
pubmed: 25591851
Recent Pat Drug Deliv Formul. 2013 Aug;7(2):150-61
pubmed: 23286513
Front Pharmacol. 2019 May 02;10:459
pubmed: 31118895
Adv Pharm Bull. 2015 Sep;5(3):305-13
pubmed: 26504751
Am J Ther. 2015 Mar-Apr;22(2):90-7
pubmed: 25581856
Drug Deliv. 2014 Nov;21(7):509-18
pubmed: 24215165
APL Bioeng. 2019 Mar 26;3(1):011502
pubmed: 31069332
Colloids Surf B Biointerfaces. 2014 Jun 1;118:154-63
pubmed: 24769392
Theranostics. 2016 Jun 07;6(9):1306-23
pubmed: 27375781
Saudi Pharm J. 2016 Sep;24(5):537-546
pubmed: 27752225
Drug Dev Ind Pharm. 2015;41(12):2089-99
pubmed: 26304493
Drug Deliv. 2018 Nov;25(1):1910-1921
pubmed: 30451015
Drug Deliv. 2015;22(6):675-90
pubmed: 24670091
Int J Pharm. 2019 May 30;563:293-303
pubmed: 30951860
Int J Pharm. 2015 Mar 1;480(1-2):128-36
pubmed: 25615987
Int J Nanomedicine. 2015 Feb 02;10:975-99
pubmed: 25678787